Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Priscilla Kincaid-SmithDavid Packham

Abstract

Several publications in the past 2 years have demonstrated that combined angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor antagonist (AIIRA) are more effective in reducing blood pressure and proteinuria in patients with chronic renal disease than ACEI or AIIRA alone. This study compares the effect of increasing the ACEI dose by 50% with that of adding an AIIRA to a standard ACEI dose. This study was designed as part of a previous comparison of ACEI with ACEI plus candesartan. Directly after completion of the randomized intervention periods of that study, the dose of ACEI was increased by 50% in all patients. Proteinuria and blood pressure were compared in both groups of patients in the three periods, on standard ACEI, on ACEI plus candesartan and on a dose of ACEI increased by 50%. No significant differences in the primary end-point proteinuria or secondary end-points were observed when the ACEI dose was increased by 50%. Proteinuria was 1.8 g in 24 h on candesartan and ACEI and 2.4 g in 24 h when the ACEI dose was increased by 50% (P<0.02). Systolic blood pressure was 126.6 mmHg on candesartan and ACEI and 134.47 mmHg when the ACEI dose was increased by 50% (P<0.002). Diastolic blood pressure, serum ...Continue Reading

Citations

Aug 16, 2006·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Mieczysław LitwinJolanta Antoniewicz
Aug 16, 2008·International Urology and Nephrology·Kostas C Siamopoulos, Rigas G Kalaitzidis
Jul 17, 2009·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·Peter Sleight
Jan 18, 2008·Nephrology·Priscilla Kincaid-SmithJoseph Proietto
Dec 31, 2010·Vascular Health and Risk Management·Maria Leonarda De Rosa
May 13, 2008·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Fausta CatapanoGiuseppe Conte
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Yoshihiko KannoHiromichi Suzuki
May 31, 2008·Expert Review of Cardiovascular Therapy·Katarzyna Kolasinska-MalkowskaAndrzej Tykarski
Jul 1, 2009·Expert Opinion on Pharmacotherapy·B Mendis, S R Page
Feb 19, 2015·The Cochrane Database of Systematic Reviews·Emma J McMahonDavid W Mudge
Nov 10, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Ashutosh Singh
Nov 8, 2006·Current Hypertension Reports·Simardeep Mangat, Steven A Atlas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.